Tel Aviv Stock Exchange Ltd. · TASE:TASE
Tel Aviv Stock Exchange — EndyMed — Investor Presentation (April 2019)
20 slides from Tel Aviv Stock Exchange's investor presentation, April 2019
Slide 1: EndyMed Investors Presentation
ENDYMED Investors Presentation April, 2019
Slide 2: Disclaimers
Disclaimers This presentation (the “Presentation”) is for informational purposes only and does not constitute or form any part of any offer for sale or subscription of, or solicitation of, any offer to buy or subscribe for any shares or other securities of EndyMed Ltd. (the “Company”) or any of its
Slide 3: 2018 ENDYMED by the numbers
2018 ENDYMED by the numbers $18.4M $10.0M 54.5% Revenue Gross Profit Gross Margin $2.1M $2.0M $1.2M EBIT Net Profit Cash from Operations
Slide 4: 2018 Financials Achievements
2018 Financials Achievements ($ thousands) ✓ Revenue increased by 5.2% (YoY) amounting to $18.4M ✓ Professional revenue increased by 2.1% (YoY) amounting to $10.5M ✓ Home use device revenue increased by 12.9% (YoY) amounting to $8.0M ✓ Record year in profitably, moving from a loss position to $2.0M
Slide 5: ENDYMED Global Presence, Sales and Distribution
ENDYMED Global Presence, Sales and Distribution USA Direct operation by Endymed Inc, NEWA Inc. ISRAEL Headquarters CHINA Strong presence by OHMK controlling shareholder and distributor for professional and home use device products Market Diversity Global Presence Effective Sales Channels Effective f
Slide 6: ENDYMED at a Glance
ENDYMED at a Glance ✓ Worldwide recognized brand ✓ Global presence in RF energy-based medical aesthetic treatments, well-adjusted worldwide geographic presence ✓ Holistic Aesthetic Approach for professional clinics, medspas and home use ✓ Committed to providing the highest standards for safe and eff
Slide 7: Management Team & Corporate Structure
Management Team & Corporate Structure ENDYMED Ltd. (TASE:ENDY) Yossi Bar-On CEO Rami Aviram CFO Curelight Medical Ltd. ENDYMED Medical Ltd. Paul Iannelli Site Manager & VP Sales North America Lior Cohen VP Sales, Professional Line ENDYMED Asia Ltd. ENDYMED Medical Inc. Sima Witman VP R&D Atzmon Ben
Slide 8: ENDYMED Overview
ENDYMED Overview Product Concept, Supply Chain, Production Sales Channels Treatment Providers Development and and Quality Control Regulatory Approval ✓ R&D Regulation & Clinical ✓ Physicians ✓ Production Protocol ✓ Direct Sales (US Market) • 13 Team Members Dermatologists and Production forecast to
Slide 9: The Demands of the Aesthetic Market
The Demands of the Aesthetic Market • Treatment options that support individuality and personal definitions of beauty • Measurable results that look natural - YOUR SKIN, JUST BETTER • Non and minimal-invasive procedures • Safer treatments with little to no down time • Pro-active aging prevention and
Slide 10: ENDYMED Professional Treatment Systems
ENDYMED Professional Treatment Systems Powerful, Easy-to-use focused RF visual user treatments - interface More power Large 15” New easy-to- 65W responsive use visual user 85W glass screen interface Supports all ENDYMED Complete head to toe treatment handpieces – facial, treatments available, Suppor
Slide 11: Complete Range of ENDYMEDs Aesthetic Treatments on One Flexible Platform
Complete Range of ENDYMEDs Aesthetic Treatments on One Flexible Platform Facial Tightening & Body Tightening & Fractional RF designated for Contouring designated for Contouring designated for • Skin texture improvements • Skin tightening and lifting • Body shaping and • Skin tightening and wrinkle r
Slide 12: The NEWA by ENDYMED Home Use Product Line
The NEWA by ENDYMED Home Use Product Line NEWA, the ENDYMED treatments are available in an easy-to-use home use skin care system The NEWA Skin Care System uses ENDYMEDs’ 3DEEP RF technology to trigger the skin’s natural collagen production. NEWA offers easy, convenient treatments in the comfort of t
Slide 13: ENDYMED Advantage
ENDYMED Advantage 3DEEP Technology Clinical Studies Results Regulatory Clearance 3DEEP technology targets the dermis ENDYMEDs’ treatment RF treatment platforms ENDYMEDs’ treatment skin layer, delivering focused and capabilities have been provide results for platforms have international controlled en
Slide 14: 2018 Financials
SUBJECT OF 2018 Financials PRESENTATION
Slide 15: Revenue Analysis Overview ($ thousands)
Revenue Analysis Overview ($ thousands) Total revenues 2011-2018 18,453 CAGR → 22% 17,541 14,252 12,951 EMEA FY2018 Revenue by geography 15% FY2018 Revenue mix 10,546 LATAM LATAM 12% 12% NA APAC 5,861 18% 18% 4,982 4,580 Total HUD 43% 2011 2012 2013 2014 2015 2016 2017 2018 EMEA EMEA 15% 15% Total P
Slide 16: Financial Analysis Overview ($ thousands)
Financial Analysis Overview ($ thousands) 2018 Profit and loss Revenue/Gross profit/Net income (loss) 20,000 18,453 17,541 14,252 FY2018 FY2017 VAR vs YoY 15,000 Act Act $ % 10,048 10,000 7,628 Revenues 18,453 17,541 913 5.2% 7,359 Cost of goods sold 8,405 10,182 1,777 17% 5,000 2,151 2,021 Gross pr
Slide 17: Financial Analysis Overview
Financial Analysis Overview Operating expenses analysis Total assets / Total liabilities / Net assets 6,000 3,886 14,000 4,000 11,748 2,318 12,000 10,384 1,778 2,000 10,000 8,804 7,532 8,000 6,353 6,399 - 5,349 FY2016 FY2017 FY2018 6,000 4,031 4,000 R&D expenses, net 1,272 2,000 - 6,000 5,184 FY2016
Slide 18: Industry Overview
Industry Overview *) Medical aesthetic treatment Improvement of cosmetic appearance of individual through treating medical and physical conditions Global sales revenue for medical aesthetic treatments: in US$ billions Global sales revenue for energy based medical aesthetic CAGR – 6% treatments by re
Slide 19: Industry – M&A
Industry – M&A *) Recent significant M&A transactions in Medical aesthetics since February 2017 Transaction highlights: Transaction highlights: Transaction highlights: • Announced Date: 14-Feb-17 • Announced Date: 13-Feb-17 • Announced Date: 03-Apr-17 • Cash Offer: $66 per share • Cash Offer: $56.5
Slide 20: Thank You
Thank You ENDYMED BDEEP SKIN SCIENCE